Pharvaris (PHVS) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Pharvaris, a biopharmaceutical company, reported a robust financial position with €305 million in cash, as it progresses its pivotal Phase 3 studies for the treatment and prevention of hereditary angioedema (HAE) using deucrictibant. The company is poised for significant advancements with its novel oral therapy, showcasing promising long-term data for both prophylactic and on-demand HAE treatments. These developments place Pharvaris at the forefront of addressing unmet needs in the HAE treatment landscape.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
